Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics attracts funding support from Chinese life sciences company

Private placement sees Lepu Medical Group take a 13% interest.
Cancer cells
New stakeholder aims to develop a position in the Chinese oncology market

Viralytics Ltd (ASX:VLA) has received a boost for its cancer treatment development work with more than $29.6 million raised in a private placement to a leading Chinese life sciences company.

Lepu Medical Group has acquired more than 36 million shares at $0.82 each and now owns circa 13% of Viralytics.

The placement price represents a 27% premium to the 30-day volume weighted average price of Viralytics shares.

Treatments for a range of cancers

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers.

The company’s lead investigational product, CAVATAK®, is being studied in clinical trials for the treatment of melanoma, as well as bladder and lung cancers.

Lepu Medical has made the investment as part of its strategic plan to expand into the field of cancer immunotherapy.

Dr Zhongjie Pu, chairman, said: “We have carefully reviewed the global oncolytic virus landscape and believe CAVATAK is the leading agent with demonstrated potential to enhance the activity of checkpoint inhibitors such as anti-PD-1 (or PD-L1) across many important cancer types.

“We also look forward to exploring possible collaborative opportunities with Viralytics as part of our goal to develop a significant position in the Chinese oncology market.”

Cash balance of more than $50 million

The placement has taken Viralytics’ cash balance to more than $50 million with another $6.4 expected from the R&D Tax Incentive program.

It will enable the Sydney-based company to accelerate its global clinical development program.

View full VLA profile View Profile

Viralytics Timeline

December 10 2015

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use